Intravenous fluid therapy is the most commonly prescribed inpatient medication in hospitals around the world. Intravenous fluids are drugs and have an indication, a dose, and expected and unintended effects. The type and amount of fluid given to patients are both important, and can either hasten or slow recovery depending on how they are administered. This narrative review provides a brief summary of the effect of intravenous fluid administration on kidney function and on renal outcome measures of relevance to both patients and clinicians. Several large clinical trials of fluid therapy are currently underway, the results of which are likely to change clinical practice.
fluid resuscitation has become one of the most ubiquitous interventions in healthcare. Advances in resuscitation fluid composition have included the use of balanced crystalloids, albumin, and synthetic starch-based colloids. Fluid choice remains a controversial topic, due largely to inconsistent and opposing results from clinical trials. The main focus of the clinical trials reviewed in this article is the association between fluid administration and adverse renal outcomes.
Renal outcomes can be defined from several perspectives: that of the physician, patient, and clinical trialist. Physicians may describe renal outcomes based upon laboratory values such as serum creatinine and urea. For patients, the more significant outcomes are those that relate to morbidity and quality of life, such as persistent renal dysfunction and requirement for renal replacement therapy. For the clinical trialist, outcomes need to encompass both the measure of function and dysfunction at the cellular and organ level, and patient-level outcomes.
Resuscitation fluid should be treated with the same level of consideration as any other prescription medication. Choosing the appropriate dose and type of fluid has significant implications for patient outcomes. 2e6 This narrative review focuses primarily on renal outcomes, although it is worth noting that the physiological implications of fluid administration extend beyond the kidney. 7 The authors discuss their current understanding of how fluid therapies impact renal function through dose and type of fluids administered, summarize recent trial data, and offer advice to physicians in order to guide practice.
Physiology
The kidney is a dynamic organ that plays a fundamental role in regulating plasma osmolality and water excretion in response to wide changes in fluid intake. During water restriction, the kidney produces more concentrated urine in an effort to conserve water. The kidney creates and maintains an osmotic gradient that becomes increasingly concentrated from the cortex to the medulla. By arranging the loops of Henle and collecting ducts in a counter-current fashion with the renal osmotic gradient, the gradient is maintained and allows for reabsorption of the majority of water that passes through the kidney. 8, 9 Urea is the primary waste product excreted by the kidney, but also plays a role in urine concentration, particularly in the inner medulla. 8 The inner medullary nephrons are differentially permeable to urea and water in the descending and ascending limbs of the loop of Henle. This helps create an osmotic gradient that aids in water reabsorption from the collecting ducts and into the vasa recta. 8, 10, 11 I.V. fluid administration is necessary to replace fluid deficits, maintain ongoing fluid requirements, and to administer medications. In the setting of critical illness, the classical model of the vascular compartment is less applicable because of increased permeability and disruption of the endothelial glycocalyx. 3 The physiologic stress of surgery can transiently mimic the physiology of critical illness, albeit in a less severe form.
Factors associated with i.v. fluid administration and adverse renal outcomes
Dose
Traditional methods of i.v. fluid dosing relied upon pre-set formulae accounting for fluid deficits and ongoing requirements that have been shown to perform poorly. Kidney function, as with most organ systems, relies upon appropriate intravascular volume in order to maintain adequate organ perfusion. Prior understanding suggested that intravascular volume expansion was universally protective of renal function, however in a large, multicentre outcomes study, Shin and colleagues 2 showed that both volume excess and insufficiency are deleterious. Liberal i.v. fluid administration can negatively impact renal function by creating alveolarcapillary edema, impairing gas exchange, and contributing to acid-base disturbances. Moderately restrictive fluid administration strategies have been shown to be associated with improved renal outcomes, 2 although the definitions of restrictive, moderate, and liberal approaches vary widely. 'Restrictive' intraoperative fluid strategies can vary from <900 ml up to 2740 m, and 'liberal' strategies vary from 2700 to 5388 ml. 2, 18 The variability in definitions of liberal and restrictive fluid doses is likely a result of the variability in clinical context. A liberal strategy for a thoracic surgical patient is likely to be different from that of a patient undergoing extensive colonic resection. Therefore, it is necessary for the clinician to determine an individual patient's fluid requirement taking into account comorbidity, current fluid status, ongoing losses, surgical duration, and the effects of fluid on the surgical site.
Type of i.v. fluid
I.V. fluids include both colloids and crystalloids, although further nuances exist within these categories. 7 Colloids include synthetic hydroxyethyl starches (HES), gelatin-based colloids, and albumin. For crystalloids, the most important distinction is between balanced and unbalanced chloride-rich fluids.
Colloids are defined by their molecular weight, level of molecular substitution, and by the crystalloid solution in which they are formulated. Colloids were initially met favourably based on the notion that they would remain in the vascular compartment longer than crystalloids, and therefore contribute less to overall fluid burden. This concept is now outdated and colloids have partially fallen out of favour as a resuscitation fluid because of a growing body of data that suggest that their use is associated with an increased incidence of acute kidney injury and decreased survival. However, the majority of these data are from critically-ill patients, and there are insufficient studies to show that this can be extrapolated to the surgical population.
Balanced vs unbalanced crystalloids
Crystalloids are ionic solutions composed of a variety of specific ions designed to mimic physiological extracellular fluid. 'Normal' saline (0.9% NaCl) contains 154 mEq of both sodium and chloride, which results in a strong ion difference of zero and a concentration of chloride that is 50% higher than in plasma. When given in sufficient quantities, this results in a hyperchloraemic metabolic acidosis. 19, 20 In contrast, balanced crystalloids substitute a portion of the chloride anion with other (organic) anions, which are rapidly metabolized and lead to bicarbonate generation. Examples of balanced crystalloids are Ringer's solution, which contains lactate, and PlasmaeLyte, which contains acetate and gluconate. Chloride-rich fluids have been implicated in increased risk of hyperchloraemic metabolic acidosis, longer hospital stays, renal injury, and mortality. 6,21e30 There are several randomizedcontrolled trials that show no overall difference in the incidence of acute kidney injury between critically-ill patients given balanced or unbalanced crystalloids. 31 However, in the recent large randomized, multiple-crossover trial by Semler and colleagues, 31 patients who received higher volumes of 0.9% saline had a higher incidence of acute kidney injury and were more likely to receive renal replacement therapy compared with those who received balanced crystalloids. Proposed mechanisms of renal injury associated with hyperchloraemia are reduced renal blood flow because of afferent arteriolar vasoconstriction, inflammation, and oedema. 22 These effects have been replicated in a study that compared starch solutions suspended in balanced crystalloids or saline. 32 
Crystalloids vs colloids
There is an ongoing debate regarding the choice between colloids and crystalloids in i.v. fluid therapy. In the 1990s, an association was identified between hypoalbuminaemia and mortality in critically ill patients. 33 The proposed mechanism for the protective effects of albumin have been free-radical scavenging, 34 improved water retention in the intravascular compartment, and water reabsorption from the interstitium. However, the physiology of stress in surgery and critical illness results in disruption of the endothelial glycocalyx, which may render some of these theoretical benefits of colloids less effective. 3 The demonstrated benefit of colloids varies between studies. A small study of 100 hypoalbuminaemic critically-ill patients who were randomized to receive albumin or not as part of their therapy showed a decrease in Sequential Organ Failure Assessment scores in the group that received albumin. 35 However, a much larger study by Finfer and colleagues 36 did not demonstrate a difference in 28-day mortality or renal outcomes in 6997 critically-ill patients who were randomized to receive 4% albumin or 0.9% saline. Two widely reported studies from Australasia and Scandinavia suggest an association between synthetic colloid administration and renal injury. Myburgh 37 and hyperoncotic plasma at the glomerulus leading to reduced glomerular ultrafiltration. 38 HES molecules greater than 50 kDa must be enzymatically degraded in the reticuloendothelial system before renal excretion. This process is slow, and can lead to vacuolization and oedema in the proximal tubules of the nephron, a process referred to as osmotic nephrosis.
Goal-directed fluid therapies
After the 2001 study by Rivers and colleagues, 39 which suggested that early goal-directed fluid resuscitation improved clinical outcomes in critically-ill patients with sepsis, there have been several studies that further explored the association between early goal-directed therapies (EGDT) and patient outcomes. Three large, multicentre, randomized, controlled trials each evaluated the effectiveness of EGDT with regards to reducing mortality and adverse renal outcomes as identified by the need for renal-replacement therapy. The Protocolized Care for Early Septic Shock (ProCESS) trial, the Australasian Resuscitation in Sepsis Evaluation (ARISE) trial, and the Protocolised Management in Sepsis (ProMISe) trials each found no reduction in mortality or need for renalreplacement therapy with utilization of EGDT.
40e42
A recent meta-analysis of the ProCESS, ARISE, and ProMISe studies performed by the Protocolized Resuscitation in Sepsis Meta-Analysis (PRISM) Investigators 43 showed that EGDT does not improve outcomes for patients with sepsis when compared with usual care. It is possible that in the years since the Rivers study, 39 'usual care' has improved, and earlier identification of sepsis, antibiotic administration, and superior supportive therapies result in improved patient outcomes, therefore reducing the potential impact of EGDT. The previously mentioned EGDT trials all focus on the critical care population. There is a relative paucity of data for intraoperative goal-directed therapy (GDT) with a specific focus on renal outcomes. However, a recent meta-analysis of 2099 patients over 23 studies by Rollins and Lobo 44 showed that while there is no mortality benefit to intraoperative GDT, there is a reduction in morbidity in patients receiving intraoperative GDT. Interestingly, no morbidity benefit is demonstrated with intraoperative GDT in patients who are on an enhanced-recovery protocol. The goals used to direct therapy in these studies were transoesophageal Doppler ultrasonography, lithium dilution, and arterial pressure wave contour analysis. There was no significant difference in total fluid volume administered between patients receiving GDT or standard care, although the total amount of fluid decreased in more recent studies. The GDT group in an early study included in the meta-analysis received 4405 ml of crystalloid compared with 4375 ml in the control group, whereas a more recent study reports 1500 ml crystalloid in the GDT group compared with 1400 ml in the control group.
Renal outcome measures

Composite outcomes
Renal outcome measures in clinical research are typically individual events or composite variables that combine several specific outcomes into one group variable. There are risks and benefits to either approach. Whilst using individual outcomes can reduce the risk of confounding, rare outcomes can be missed and larger sample sizes are required. Using a composite outcome measure increases the overall event rate (and thus makes it easier to find evidence of an effect of an intervention) but is not without problems, such as that of competing risk. In the composite outcome described later [Major Adverse Kidney Events in the first 30 days (MAKE30)], patients cannot experience the sustained worsened renal function component if they die before Day 30. This conceptecompeting riskemust be minimized if a composite outcome measure is used for a clinical trial.
In perioperative clinical trials that study renal function, we advocate use of MAKE30. 45 This outcome is defined as the occurrence of any of the following: in-hospital mortality, new renal replacement therapy, or sustained worsened renal function at 30 days after intensive care unit (ICU) admission. Persistent renal dysfunction can be defined as a 200% increase in serum creatinine from admission to discharge. 46 Such a large increase in creatinine has the potential to miss cases of milder renal impairment, however this reduced sensitivity is accompanied by increased specificity, and there is no doubt of its clinical relevance. Although a timeframe of 30 days resonates with physicians, assessment at 90 days (MAKE90) provides a more logical link to the incidence (or progression) of chronic kidney disease. The overall incidence of MAKE30 in adult ICU populations is in the 15e20% range depending on the severity of the acute illness and underlying cause of disease. The Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE), 47 Acute Kidney Injury Network (AKIN), 48 and Kidney Disease: Improving Global Outcomes (KDIGO) 49 classifications are all systems that define several strata of acute kidney injury based on proportional increases in serum creatinine and decreases in urine output. Urine output is a potentially problematic element of these criteria, as it is recorded inconsistently, particularly in patients who are not in a critical-care setting, and therefore less likely to have a urinary catheter. Whilst serum creatinine likely offers a more robust metric for kidney injury, it is also imperfect as it is affected by ethnicity, body-mass, age, sex, diet, and medications.
Biomarkers
The traditional biomarker for renal injury is serum creatinine, and is often assessed in conjunction with urine output. Both of these measures are insufficiently sensitive, are confounded by factors such as muscle mass, and usually alert the physician to kidney injury after significant damage has occurred.
Therefore, there has been a desire to identify biomarkers for early kidney injury. The three biomarkers with the most data currently are tissue inhibitor of metalloproteinase 2 (TIMP2) 50 , insulin-like growth factor-binding protein 7 (IGFBP7), 50 and neutrophil gelatinase-associated lipocalin (NGAL). 51 However, there are several issues relating to these biomarkers. TIMP2 and IGFBP7 are released during the G1 arrest portion of renal tubular cell cycles, which occurs during renal tubular stress. NGAL is released after either renal ischaemia or direct nephrotoxicity, and has been suggested to be most effective in predicting radiocontrast-induced kidney injury. NGAL can only predict kidney injury in patients with previously healthy kidneys. Kidney injury is usually a multifactorial process, so these markers might not have sufficient sensitivity or specificity when used in isolation.
When planning future clinical trials, it is important to agree upon standardized and validated clinical endpoints so that clinically meaningful comparisons can be made between studies. 52 We believe that MAKE30 45 is a reasonable start, particularly in view of its patient-centred nature.
Summary recommendations
Intravenous fluids should be treated as prescription medications, which indeed they are medicines as they are given under a specified prescriber's authority. The appropriate fluid type and dose should be carefully chosen for each individual patient, acknowledging that critical illness is a dynamic and fluctuating state. Traditional methods of estimating fluid deficit and ongoing losses should be replaced by dynamic measures of fluid responsiveness such as pulse pressure variation and ultrasonographic measurement of fluctuations in inferior vena caval diameter. Current literature supports use of balanced instead of high chloride crystalloid solutions in the critical care population in most situations, but albumin solutions can be indicated in specific settings with high fluid demands, in order to spare excessive interstitial volume loading. It remains unclear whether this can be extrapolated to intraoperative fluid management.
Conclusions
Adverse renal outcomes are associated with significantly increased morbidity, mortality, and cost. Dose and type of i.v. fluid administered are implicated in renal outcomes, therefore it is important to use the appropriate fluid. Balanced crystalloids are probably the safest choice for the widest range of resuscitative situations, although albumin solutions can also be used judiciously. Previous methods for estimating fluid requirements are outdated, and have not been proved to improve outcomes; dynamic estimations of fluid requirements are more accurate. It is important to use standard outcome metrics of kidney injury. As data grows for kidney injury biomarkers, we might be able to improve on the accuracy of current metrics. 
